The U.S. red biotechnology market size is calculated at USD 157.9 billion in 2024 and is predicted to reach around USD 271.3 billion by 2034, expanding at a CAGR of 5.56% from 2024 to 2034.
Red biotechnology refers to the field of biotechnology focusing on healthcare and pharmaceuticals in the medical field. It expands through widespread applications of biotechnology related to clinical trials, drug development process, research on disease, production of antibiotics, creation of vaccines and molecular diagnostics. Being the largest branch of biotechnology influenced by public interest, the red biotechnology field is expected to evolve with increased focus on genetics based application areas such as gene therapy and regenerative medicine in the imminent years.
The ongoing advancements in research and development in the biopharmaceutical industries, increasing investments by public and private sectors, surging demand for personalized treatments, presence of major market players and advanced healthcare infrastructure are fuelling the market growth of red biotechnology applications in the U.S. The ability of controlling human diseases is largely influenced by the evolution of red biotechnology.
However, the higher costs for development of biotechnology based products, insufficiency of funds in many biopharmaceutical companies, extensive drug development process and the stringent guidelines imposed by the regulatory agencies are restraining the market growth. Additionally, the expiration of patents, pricing pressure for consumer convenience and the use expensive technologies and equipment affect the financial growth of companies trying to expand their product portfolio for better market reach.
The investments made by the U.S. government through various agencies such as the Department of Energy (DOE), the Department of Agriculture (USDA), Department of Commerce’s Bureau of Industry and Security (BIS) and the White House state the active involvement of the government in improving human lives and safeguarding the responsible utilisation of biotechnology while addressing the issues related to climate change. The ultimate motive of the government in the red biotechnology market is to use renewable biomass by developing alternative processes for production of chemicals and materials, expansion of domestic biomanufacturing capacity, creation of climate-focused agricultural systems and plants, better lucidity and organization in the regulatory framework, conservation of fossil fuels and more focus on recycling of chemicals and materials.
Artificial intelligence (AI), machine learning tools and deep learning methodologies are widely implemented in the vast applications of red biotechnology field for improving the accuracy of results. AI algorithms can be applied for streamlining drug development and manufacturing process, in early disease detection and prediction, protein designing, in gene editing, identification of potential biomarkers and development of personalized treatment strategies for patients among various other applications. Integration of AI-driven technologies in red biotechnology is transforming the R&D approach for developing innovative solutions aimed towards enhancing patient care, environment sustainability while adhering to the stringent regulations thereby enhancing the reliability of researchers, companies and healthcare providers for utilising this technology efficiently.
Growing trend of outsourcing services by various biopharmaceutical companies in the U.S. through various outsourcing organizations such as Contract Development and Manufacturing Organization (CDMO), Contract Manufacturing Organizations (CMO) and Clinical Research Organizations
(CROs) offering cost-effective and streamlined processes for drug development and manufacturing processes as well as assistance in the clinical trial process has been driving the growth red biotechnology market in the U.S.
Ongoing advancements in genetic research, increased focus on regenerative medicine, rising investments in R&D of biopharmaceuticals and innovative treatments, initiatives for implementing sustainable agriculture, surging demand for personalized medicine and growing government support are the expected to create opportunities for the growth of red biotechnology market in the U.S. in the upcoming years.
Published by Ajit Bansod
